KR101892330B1 - 항응혈 역전 물질들 - Google Patents

항응혈 역전 물질들 Download PDF

Info

Publication number
KR101892330B1
KR101892330B1 KR1020147016304A KR20147016304A KR101892330B1 KR 101892330 B1 KR101892330 B1 KR 101892330B1 KR 1020147016304 A KR1020147016304 A KR 1020147016304A KR 20147016304 A KR20147016304 A KR 20147016304A KR 101892330 B1 KR101892330 B1 KR 101892330B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dap
anticoagulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147016304A
Other languages
English (en)
Korean (ko)
Other versions
KR20140107259A (ko
Inventor
솔로몬 에스 스테이너
브라이언 이 라울리츠트
사샤 에이치 바크루
에디트 마티오비츠
Original Assignee
페로스피어 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101892330(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 페로스피어 파마슈티컬스 인코포레이티드 filed Critical 페로스피어 파마슈티컬스 인코포레이티드
Publication of KR20140107259A publication Critical patent/KR20140107259A/ko
Application granted granted Critical
Publication of KR101892330B1 publication Critical patent/KR101892330B1/ko
Assigned to 코비스 파마 게엠베하 reassignment 코비스 파마 게엠베하 권리의 전부이전등록 Assignors: 페로스피어 파마슈티컬스 인코포레이티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147016304A 2011-11-29 2012-11-29 항응혈 역전 물질들 Active KR101892330B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US61/564,559 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US61/614,292 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US61/641,698 2012-05-02
US201261666291P 2012-06-29 2012-06-29
US61/666,291 2012-06-29
PCT/US2012/066938 WO2013082210A1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Publications (2)

Publication Number Publication Date
KR20140107259A KR20140107259A (ko) 2014-09-04
KR101892330B1 true KR101892330B1 (ko) 2018-08-27

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147016304A Active KR101892330B1 (ko) 2011-11-29 2012-11-29 항응혈 역전 물질들

Country Status (34)

Country Link
US (5) US9522892B2 (https=)
EP (1) EP2785700B1 (https=)
JP (1) JP6134731B2 (https=)
KR (1) KR101892330B1 (https=)
CN (1) CN104080772B (https=)
AP (1) AP2014007662A0 (https=)
AR (1) AR089020A1 (https=)
AU (1) AU2012345975B2 (https=)
BR (1) BR112014012892B1 (https=)
CA (1) CA2856540C (https=)
CL (1) CL2014001399A1 (https=)
CO (1) CO6990738A2 (https=)
CR (1) CR20140310A (https=)
CY (1) CY1117414T1 (https=)
DK (1) DK2785700T3 (https=)
EA (1) EA027603B1 (https=)
EC (1) ECSP14006696A (https=)
ES (1) ES2569674T3 (https=)
HR (1) HRP20160513T1 (https=)
HU (1) HUE027452T2 (https=)
IL (1) IL232788B (https=)
ME (1) ME02424B (https=)
MX (1) MX349514B (https=)
PE (1) PE20141295A1 (https=)
PH (1) PH12014501176A1 (https=)
PL (1) PL2785700T3 (https=)
PT (1) PT2785700E (https=)
RS (1) RS54738B1 (https=)
SG (1) SG11201402713WA (https=)
SI (1) SI2785700T1 (https=)
SM (1) SMT201600161B (https=)
UA (1) UA116336C2 (https=)
WO (1) WO2013082210A1 (https=)
ZA (1) ZA201404793B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999690B2 (en) 2013-11-08 2018-06-19 Perosphere Pharmaceuticals Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
WO2019094959A1 (en) * 2017-11-13 2019-05-16 Fernandez Joss Reconstitution of post mortem circulation, specialized methods and procedures
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN118684672A (zh) 2023-03-24 2024-09-24 陕西麦科奥特科技有限公司 一种抗凝逆转剂及其制备方法和应用
CN117624137A (zh) * 2023-12-04 2024-03-01 中国药科大学 三嗪骨架小分子肝素逆转剂及其制备方法与用途
US20250389737A1 (en) * 2024-06-20 2025-12-25 Instrumentation Laboratory Company FACTOR Xa REAGENT
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent
CN121622691A (zh) * 2024-08-30 2026-03-10 陕西麦科奥特医药科技股份有限公司 使用抗凝逆转剂治疗抗凝剂导致的出血的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
WO1998016547A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
JP2001519806A (ja) * 1997-04-07 2001-10-23 アクシス ファーマシューティカルズ，インコーポレイティド セリンプロテアーゼ活性、特にトリプターゼ活性に関連する疾病を処理するための化合物及び組成物
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
NZ514877A (en) 1999-05-19 2004-10-29 Pharmacia Corp Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CA2405684A1 (en) 2000-04-17 2001-10-25 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
AU2001275857A1 (en) * 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
EP1438292A1 (en) 2001-10-03 2004-07-21 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US20060148734A1 (en) * 2002-03-27 2006-07-06 Patrick Camilleri Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
JPWO2003099324A1 (ja) * 2002-05-23 2005-09-22 中外製薬株式会社 組織因子阻害剤中和剤及び活性型血液凝固第ｖｉｉ因子製剤中和剤
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2008105441A1 (ja) * 2007-02-27 2008-09-04 Ajinomoto Co., Inc. リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Crowther et al., Blood 111, 4871-4879, 2008
Kitamura et al., J. Med. Chem. 44, 2438-2450, 2001

Also Published As

Publication number Publication date
PH12014501176B1 (en) 2014-09-01
IL232788A0 (en) 2014-08-03
PE20141295A1 (es) 2014-10-01
PH12014501176A1 (en) 2014-09-01
IL232788B (en) 2018-05-31
NZ625337A (en) 2016-11-25
ZA201404793B (en) 2015-04-29
CN104080772A (zh) 2014-10-01
SMT201600161B (it) 2016-07-01
US9877961B2 (en) 2018-01-30
PT2785700E (pt) 2016-06-02
AU2012345975B2 (en) 2016-12-15
EP2785700B1 (en) 2016-03-09
EA201490823A1 (ru) 2015-01-30
SG11201402713WA (en) 2014-06-27
SI2785700T1 (sl) 2016-09-30
AU2012345975A1 (en) 2014-05-29
ES2569674T3 (es) 2016-05-12
EA027603B1 (ru) 2017-08-31
CA2856540A1 (en) 2013-06-06
PL2785700T3 (pl) 2016-09-30
CR20140310A (es) 2014-08-20
US20240366592A1 (en) 2024-11-07
CY1117414T1 (el) 2017-04-26
CO6990738A2 (es) 2014-07-10
KR20140107259A (ko) 2014-09-04
UA116336C2 (uk) 2018-03-12
EP2785700A1 (en) 2014-10-08
BR112014012892A2 (pt) 2017-06-13
DK2785700T3 (en) 2016-06-13
US20180207152A1 (en) 2018-07-26
US20170056396A1 (en) 2017-03-02
JP6134731B2 (ja) 2017-05-24
AR089020A1 (es) 2014-07-23
US9522892B2 (en) 2016-12-20
JP2014534270A (ja) 2014-12-18
CA2856540C (en) 2018-04-03
HRP20160513T1 (hr) 2016-07-15
HK1202858A1 (en) 2015-10-09
RS54738B1 (sr) 2016-10-31
WO2013082210A1 (en) 2013-06-06
US20130137702A1 (en) 2013-05-30
CN104080772B (zh) 2016-10-05
MX349514B (es) 2017-08-02
HUE027452T2 (en) 2016-09-28
ME02424B (me) 2016-09-20
US20210169874A1 (en) 2021-06-10
BR112014012892B1 (pt) 2022-12-20
ECSP14006696A (es) 2015-06-30
AP2014007662A0 (en) 2014-05-31
MX2014006349A (es) 2014-09-04
BR112014012892A8 (pt) 2021-06-08
CL2014001399A1 (es) 2014-11-03

Similar Documents

Publication Publication Date Title
KR101892330B1 (ko) 항응혈 역전 물질들
CN1078070C (zh) 苯并噻吩衍生物在制备抑制凝血酶药物中的用途
US20120202850A1 (en) Method for treating thrombosis and inhibiting platelet aggregation with 21-(s)-argatroban
JPH06192291A (ja) 新規ペプチドとそれを用いた血小板凝集抑制剤及び血液凝固抑制剤
JP2002501936A (ja) 低分子量ヘパリンをＧＰＩＩｂ／ＩＩＩａ拮抗物質と組合わせて使用する血小板凝集の抑制
EP4692086A1 (en) Anticoagulation reversal agent, and preparation method therefor and use thereof
CN1446101A (zh) 包括凝血酶抑制化合物和凝血因子Vlla抑制剂的复合产物
HK1202858B (en) Anticoagulant reversal agents
OA16905A (en) Anticoagulant reversal agents.
CA2230445C (en) Fibrinogen receptor antagonists and medicinal preparations containing the same as the active ingredient
NZ625337B2 (en) Anticoagulant reversal agents
HK40115555A (zh) 一种抗凝逆转剂及其制备方法和应用
WO2026046334A1 (zh) 使用抗凝逆转剂治疗抗凝剂导致的出血的方法
JP2004511489A (ja) ポリヒドロキシアルキル基およびポリヒドロキシシクロアルキル基を有するセリンプロでアーゼの低分子インヒビター
JPWO1989011852A1 (ja) 膵炎等治療剤
EP3184095A1 (en) Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
WO2003089426A1 (en) Medicine for prevention and/or therapy of disseminated intravascular coagulation syndrome

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20210715

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20220718

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)